Evidence map›Paper›PMID 33333627›Full record

ArticleTransfusion medicine (Oxford, England)2021

Convalescent plasma therapy for the treatment of patients with COVID-19: Assessment of methods available for antibody detection and their correlation with neutralising antibody levels.

Heli Harvala, Matthew L Robb, Nick Watkins, Samreen Ijaz, Steven Dicks, Monika Patel, Piyada Supasa, Dejnirattisai Wanwisa, Chang Liu, Juthathip Mongkolsapaya and 17 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Transfusion medicine (Oxford, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
72citing papers in PubMed, 3 pooled it
2.1field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

72 citing papers in PubMed, 3 syntheses or guidelines pooled it, 87 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Article
  9. Quantitative and Standardized Pseudovirus Neutralization Assay for COVID-19.Methods in molecular biology (Clifton, N.J.) · 2024
    Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

12 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

27 authors at 6 institutions in 2 countries.

Heli HarvalaNational Microbiology Services, NHS Blood and Transplant, London, UK.ORCID https://orcid.org/0000-0001-9154-4190
Matthew L RobbStatistics and Clinical Studies, NHS Blood and Transplant, Bristol, UK.
Nick WatkinsDepartment of Research and Development, NHS Blood and Transplant Cambridge, Cambridge, UK.
Samreen IjazVirology Reference Department, National Infection Service, Public Health England, London, UK.
Steven DicksVirology Reference Department, National Infection Service, Public Health England, London, UK.
Monika PatelHigh Containment Microbiology, National Infection Service, Public Health England, London, UK.
Piyada SupasaWellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Dejnirattisai WanwisaWellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Chang LiuWellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Juthathip MongkolsapayaWellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Abbie BownRare and Imported Pathogens Laboratory, Public Health England, Porton Down, Wiltshire, UK.
Daniel BaileyRare and Imported Pathogens Laboratory, Public Health England, Porton Down, Wiltshire, UK.
Richard VipondRare and Imported Pathogens Laboratory, Public Health England, Porton Down, Wiltshire, UK.
Nicholas GraysonDepartment of Paediatric Medicine, University of Oxford, University of Oxford, Oxford, UK.
Nigel TempertonMedway School of Pharmacy, University of Kent, Chatham, UK.
Sunetra GuptaDepartment of Zoology, University of Oxford, Oxford, UK.
Rutger J PloegNuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.
Jai BoltonDepartment of Zoology, University of Oxford, Oxford, UK.
Alex FyfeDepartment of Zoology, University of Oxford, Oxford, UK.
Robin GopalVirology Reference Department, National Infection Service, Public Health England, London, UK.
Peter SimmondsNuffield Department of Medicine, University of Oxford, Oxford, UK.
Gavin ScreatonWellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Craig ThompsonDepartment of Zoology, University of Oxford, Oxford, UK.
Tim BrooksRare and Imported Pathogens Laboratory, Public Health England, Porton Down, Wiltshire, UK.
Maria ZambonVirology Reference Department, National Infection Service, Public Health England, London, UK.
Gail MiflinDepartment of Chief Medical Officer, NHS Blood and Transplant, Bristol, UK.
David J RobertsNHS Blood and Transplant, Oxford, John Radcliffe Hospital, Oxford, UK.ORCID https://orcid.org/0000-0003-0648-6585
Public Health England · GBUniversity of Oxford · GBNHS Blood and Transplant · GBCentre for Human Genetics · GBMedway School of Pharmacy · GBSiriraj Hospital · TH

Funding

Department of Health and Social Care (DHSC)/UKRI/NIHR COVID-19 Rapid Response Grant (COV19-RECPLA)European Research Council 812816Public Health England
6 · The paper itself

Abstract

introductionThe lack of approved specific therapeutic agents to treat coronavirus disease (COVID-19) associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has led to the rapid implementation of convalescent plasma therapy (CPT) trials in many countries, including the United Kingdom. Effective CPT is likely to require high titres of neutralising antibody (nAb) in convalescent donations. Understanding the relationship between functional neutralising antibodies and antibody levels to specific SARS-CoV-2 proteins in scalable assays will be crucial for the success of a large-scale collection. We assessed whether neutralising antibody titres correlated with reactivity in a range of enzyme-linked immunosorbent assays (ELISA) targeting the spike (S) protein, the main target for human immune response.

methodsBlood samples were collected from 52 individuals with a previous laboratory-confirmed SARS-CoV-2 infection. These were assayed for SARS-CoV-2 nAbs by microneutralisation and pseudo-type assays and for antibodies by four different ELISAs. Receiver operating characteristic (ROC) analysis was used to further identify sensitivity and specificity of selected assays to identify samples containing high nAb levels.

resultsAll samples contained SARS-CoV-2 antibodies, whereas neutralising antibody titres of greater than 1:20 were detected in 43 samples (83% of those tested) and >1:100 in 22 samples (42%). The best correlations were observed with EUROimmun immunoglobulin G (IgG) reactivity (Spearman Rho correlation coefficient 0.88; p < 0.001). Based on ROC analysis, EUROimmun would detect 60% of samples with titres of >1:100 with 100% specificity using a reactivity index of 9.1 (13/22). DISCUSSION: Robust associations between nAb titres and reactivity in several ELISA-based antibody tests demonstrate their possible utility for scaled-up production of convalescent plasma containing potentially therapeutic levels of anti-SARS-CoV-2 nAbs.

Indexed as

Antibodies, NeutralizingAntibodies, ViralBlood DonorsCOVID-19COVID-19 SerotherapyCOVID-19 TestingEnzyme-Linked Immunosorbent AssayHumansImmunization, PassiveMaleROC CurveSARS-CoV-2Sensitivity and SpecificityAntibodies, NeutralizingAntibodies, Viralconvalescent plasmaCOVID-19neutralising antibody levelSARS-CoV-2testing of plasma

Identifiers

PMID33333627
PMCPMC8246874
OpenAlexW3110775226

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.